1,697 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Acquired by Blueshift Asset Management LLC

Blueshift Asset Management LLC bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the first quarter, HoldingsChannel.com reports. The firm bought 1,697 shares of the biotechnology company’s stock, valued at approximately $523,000.

Several other hedge funds and other institutional investors have also bought and sold shares of UTHR. US Bancorp DE raised its position in shares of United Therapeutics by 12.2% in the 1st quarter. US Bancorp DE now owns 1,971 shares of the biotechnology company’s stock worth $608,000 after acquiring an additional 215 shares in the last quarter. Natixis Advisors LLC grew its stake in United Therapeutics by 763.4% in the first quarter. Natixis Advisors LLC now owns 118,582 shares of the biotechnology company’s stock valued at $36,556,000 after purchasing an additional 104,847 shares during the last quarter. Seizert Capital Partners LLC raised its holdings in United Therapeutics by 203.3% in the first quarter. Seizert Capital Partners LLC now owns 121,970 shares of the biotechnology company’s stock worth $37,600,000 after purchasing an additional 81,752 shares in the last quarter. Arkadios Wealth Advisors purchased a new stake in shares of United Therapeutics during the first quarter valued at about $301,000. Finally, Vestcor Inc boosted its holdings in shares of United Therapeutics by 36.4% in the 1st quarter. Vestcor Inc now owns 1,928 shares of the biotechnology company’s stock valued at $594,000 after buying an additional 515 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other news, Director Richard Giltner sold 3,036 shares of the company’s stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total value of $879,225.60. Following the sale, the director directly owned 19,384 shares of the company’s stock, valued at $5,613,606.40. This represents a 13.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James Edgemond sold 12,000 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the completion of the sale, the chief financial officer owned 8,118 shares in the company, valued at $2,641,353.66. The trade was a 59.65% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 70,681 shares of company stock worth $21,318,359. 10.30% of the stock is owned by company insiders.

United Therapeutics Price Performance

Shares of UTHR opened at $294.28 on Friday. The company’s fifty day moving average price is $298.13 and its 200-day moving average price is $313.59. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $417.82. The firm has a market capitalization of $13.27 billion, a PE ratio of 11.49, a price-to-earnings-growth ratio of 5.97 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). The firm had revenue of $798.60 million for the quarter, compared to analysts’ expectations of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm’s revenue for the quarter was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.85 EPS. As a group, research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on UTHR shares. HC Wainwright set a $400.00 price objective on shares of United Therapeutics and gave the stock a “buy” rating in a research note on Thursday. Bank of America cut their price target on shares of United Therapeutics from $321.00 to $315.00 and set a “neutral” rating on the stock in a report on Wednesday, June 11th. Wells Fargo & Company decreased their price objective on United Therapeutics from $314.00 to $295.00 and set an “equal weight” rating for the company in a report on Thursday. JPMorgan Chase & Co. lowered their price objective on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research report on Tuesday, July 8th. Finally, Wall Street Zen downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $379.69.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.